GlassScriptPhysician profile
Mark J Lobo
NPI 1780819466
$1,079.58
in general payments reported to CMS, 2019-2025
17 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $25.92 · 2021: $23.66 · 2022: $168 · 2023: $300 · 2024: $113 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $580.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $319.49 | 2019-2025 | |
| Elekta, INC. | $160.03 | 2019-2023 | Elekta Medical Linear Accelerator |
| Genzyme Corporation | $141.32 | 2019-2025 | |
| Boston Scientific Corporation | $101.38 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $78.48 | 2023 | |
| Progenics Pharmaceuticals, INC. | $39.14 | 2023-2024 | Pylarify |
| Amgen INC. | $31.25 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $27.01 | 2024 | |
| Bioprotect Medical, INC. | $25.23 | 2025 | Bioprotect Balloon Implant System |
| Beone Medicines USA, INC. | $23.90 | 2025 | Brukinsa |
| Myovant Sciences INC. | $23.66 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.77 | 2024 | Fruzaqla |
| Siemens Medical Solutions USA, INC. | $20.80 | 2025 | Eclipse Treatment Planning System For External Beam Radiation Therapy, Varian Ethos Treatment Planning |
| Agios Pharmaceuticals, INC. | $19.91 | 2024 | Pyrukynd |
| Glaxosmithkline, LLC. | $17.95 | 2025 | Zejula |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $15.91 | 2023 | Optune |
| Astrazeneca Pharmaceuticals LP | $11.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lobo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.